P
Closed
Patient-Partnered Collaborations for Rare Neurodegenerative Disease RFA
Patient-partnered research on rare neurodegenerative disease
Last Update: April 21, 2026
Funding available
$ 2,000,000
Timeline
- Open Date : February 1, 2022
- Closing date : May 24, 2022
Location
Canada
Overview
This program provides up to $2,000,000 over four years for patient-partnered research on rare neurodegenerative disease. It supports discovery science projects on disease mechanisms, patient collaboration, data sharing, and open science.
/100
Opportunity Score
Moderate potential, but conditions must align.
At a glance
Funding available
Financing goals
- Develop strategic partnerships
- Increase social or community impact
- Conduct research and development activities
Eligible Funding
- Maximum amount : 2,000,000 $
Timeline
- Open Date : February 1, 2022
- Closing date : May 24, 2022
Eligible candidates
Eligible Industries
- Professional, scientific and technical services
- Health care and social assistance
Location
- Canada
Legal structures
- All legal structures
Annual revenue
- All revenue ranges
Organisation size
- All organization sizes
Audience
- All groups
Next Steps
1
Determine your project
2
Validate your eligibility
Activities funded
- Discovery science on rare neurodegenerative disease mechanisms
- Projects addressing causes, progression, and biological mechanisms
- Cross-disease and data-centered research on rare neurological disorders
- Longitudinal studies and model development tied to specific research questions
Documents Needed
- Institutional Approval Form
- Project proposal PDF
- Budget description PDF
- Biosketches or resumes for the Coordinating PI, Lead Patient Organization PI, and co-PIs
Eligibility
Who is eligible?
- Nonprofit organizations
- Public and private research institutions
- Universities, colleges, hospitals, and laboratories
- State, local, and federal government research entities
Who is not eligible
- For-profit organizations as funding recipients
- Individuals applying on their own
- Meta employees and employees of Chan Zuckerberg Initiative, LLC
Eligible expenses
- Personnel costs
- Supplies and equipment
- Travel and meeting costs
- Subcontracts and other project costs
- Indirect costs up to the stated limit
Ineligible Costs and Activities
- Clinical trials
- Pre-clinical work mainly for clinical trial readiness
- Tool or resource development not tied to a specific research plan
- Travel expenses to the United States for international grantees
- Funding for for-profit organizations as recipients
Eligible geographic areas
- Research institutions based in any country
- Patient organizations based in the U.S. or outside the U.S.
Processing and Agreement
- Applications are externally reviewed by experts in relevant fields.
- CZI staff make final decisions with scientific advisors.
- Funding is not guaranteed, and no set number of awards is promised.
- Applicants are notified of decisions by the stated timeline.
- Annual reports are required during the award period.
Additional information
- Only one application may be submitted per Coordinating PI and per patient organization.
- Applications must be submitted through CZI’s online grants portal.
- Annual reports and progress reporting are required during the award period.
- Successful projects must follow open science, data sharing, and publication policies.
Contacts
Frequently Asked Questions about the Patient-Partnered Collaborations for Rare Neurodegenerative Disease RFA Program
Here are answers to the most common questions about the Patient-Partnered Collaborations for Rare Neurodegenerative Disease RFA. This section explains what the program is, how much funding is available, eligibility requirements, application deadlines, and other important details to help you determine if this grant is right for your business.
What is the Patient-Partnered Collaborations for Rare Neurodegenerative Disease RFA?
This program provides up to $2,000,000 over four years for patient-partnered research on rare neurodegenerative disease. It supports discovery science projects on disease mechanisms, patient collaboration, data sharing, and open science.
How much funding can be received?
Patient-Partnered Collaborations for Rare Neurodegenerative Disease RFA Funds up to $2,000,000 of admissible expenses.
What is the deadline to apply?
The application deadline for this grant program was May 24, 2022.
Who is eligible for the Patient-Partnered Collaborations for Rare Neurodegenerative Disease RFA program?
To be eligible for the Patient-Partnered Collaborations for Rare Neurodegenerative Disease RFA program, you must:
Collaborative patient-research team
Coordinating PI at research institution
Patient-led rare disease organization
What expenses are eligible under Patient-Partnered Collaborations for Rare Neurodegenerative Disease RFA?
Discovery science on rare neurodegenerative disease mechanisms
Projects addressing causes, progression, and biological mechanisms
Cross-disease and data-centered research on rare neurological disorders
Longitudinal studies and model development tied to specific research questions
Who can I contact for more information about the Patient-Partnered Collaborations for Rare Neurodegenerative Disease RFA?
You can contact Chan Zuckerberg Initiative (CZI) by email at sciencegrants@chanzuckerberg.com or by phone at none.
Where is the Patient-Partnered Collaborations for Rare Neurodegenerative Disease RFA available?
The Patient-Partnered Collaborations for Rare Neurodegenerative Disease RFA program is available across Canada.